Related Experiment Video
Updated: Jan 29, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Doxecitine and Doxribtimine: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.
Abstract:
Doxecitine and doxribtimine (KYGEVVI®) are pyrimidine nucleosides developed by UCB for the treatment of thymidine kinase 2 deficiency (TK2d). In November 2025, doxecitine and doxribtimine received its first approval in the USA for the treatment of TK2d in adult and pediatric patients with an age of symptom onset on or before 12 years. This article summarizes the milestones in the development of doxecitine and doxribtimine leading to this first approval for TK2d.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Obedience
Ethics in Research

